Tunlametinib

Tunlametinib
Clinical data
Other namesHL-085
ATC code
  • None
Legal status
Legal status
  • Rx in China
Identifiers
  • 4-Fluoro-5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H12F2IN3O3S
Molar mass491.25 g·mol−1

Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhbitor of mitogen-activated protein kinase kinase.[1]

In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.[2][3]

It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.[4]

References

  1. ^ "Tunlametinib". NCI Drug Dictionary. National Cancer Institute.
  2. ^ "Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy". 18 March 2024.
  3. ^ Keam SJ (2024). "Tunlametinib: First Approval". Drugs. 84 (8): 1005–1010. doi:10.1007/s40265-024-02072-x. PMID 39034326.
  4. ^ Shi Y, Han X, Zhao Q, Zheng Y, Chen J, Yu X, et al. (2024). "Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study". Experimental Hematology & Oncology. 13 (1): 60. doi:10.1186/s40164-024-00528-0. PMC 11167782. PMID 38867257.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.